QuidelOrtho Corporation QDEL R2K
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -5.8% CAGR over 5 years.
- Earnings shrank at -102.1% CAGR over 5 years.
- Trading 63.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QDEL QuidelOrtho Corporation R2K | 13.02 | - | $887.85M | - | -19.25% | -49.95% | -5.80% | -102.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 176.60M | 509.80M | 1.00B | 613.40M | 783.80M | 846.10M | 665.10M | 744.00M | 711.00M | 637.00M | - | - | 692.80M | 613.90M | 699.90M | 723.60M | 619.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 349.50M | 339.00M | 364.30M | 403.20M | 356.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 343.30M | 274.90M | 335.60M | 320.40M | 263.80M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 294.60M | 276.70M | 290.40M | 357.70M | 291.20M |
| Operating Income | - | 23.30M | 281.80M | 620.70M | 79.70M | 56.80M | 99.60M | -26.90M | 26.30M | -1.76B | -117.50M | - | - | 48.70M | -1.80M | 45.20M | -37.30M | -27.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.60M | -76.40M | -597.00M | 50.20M | 81.40M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.30M | 42.90M | 47.80M | 50.10M | 48.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.80M | -229.60M | -756.90M | -112.40M | -79.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.90M | 25.80M | -23.90M | 18.30M | 12.30M |
| Net Income | 178.10M | 19.10M | 215.70M | 479.90M | 19.30M | 19.20M | 48.80M | -53.20M | -12.70M | -1.71B | -147.70M | - | - | -12.70M | -255.40M | -733.00M | -130.70M | -91.80M |
| Diluted EPS | - | 0.45 | 5.08 | 11.31 | 0.36 | 0.28 | 0.73 | -0.80 | -0.19 | -25.50 | -2.20 | - | - | -0.19 | -3.77 | -10.78 | -1.92 | -1.35 |
| R&D Expense | - | 22.60M | 23.70M | 26.40M | 34.20M | 65.60M | 62.30M | 62.40M | 61.50M | 59.20M | 56.30M | 55.90M | - | 53.20M | 45.70M | 41.50M | - | 44.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.66B | - | 1.70B | 3.27B | 3.27B | 3.00B | 2.78B | 2.73B |
| Cost of Revenue | - | - | - | 1.33B | - | 1.50B | 1.50B | 1.46B |
| Gross Profit | - | - | - | 1.94B | - | 1.50B | 1.29B | 1.27B |
| Operating Expenses | - | - | - | 953.70M | - | 1.24B | 1.24B | 1.22B |
| Operating Income | 1.06B | - | 906.00M | 982.50M | 843.70M | 257.00M | 45.80M | 54.80M |
| EBITDA | - | - | - | 1.09B | - | 607.00M | -1.49B | -482.60M |
| Interest Expense | - | - | - | 74.50M | - | 178.90M | 188.30M | 183.10M |
| Pretax Income | - | - | - | 735.90M | - | -29.10M | -2.13B | -1.11B |
| Tax Provision | - | - | - | 187.20M | - | -19.00M | -79.50M | 24.10M |
| Net Income | 810.30M | - | 704.20M | 548.70M | 548.70M | -10.10M | -2.05B | -1.13B |
| Diluted EPS | 18.60 | 16.43 | 16.43 | 9.56 | 9.56 | -0.15 | -30.16 | - |
| R&D Expense | 84.30M | - | 95.70M | - | 187.90M | 245.00M | 218.70M | 186.20M |
Compounded Sales Growth
| 5 Years: | -5.80% |
| 1 Year: | -10.50% |
Compounded Profit Growth
| 5 Years: | -102.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -57.55% |
| 6 Months: | -53.73% |
| 3 Months: | -42.74% |
| 1 Month: | +13.32% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 2.43B | 8.86B | 8.86B | 8.56B | 6.42B | 5.77B |
| Current Assets | - | - | - | - | 1.58B | - | 1.31B | 1.22B | 1.45B |
| Cash & Equivalents | - | - | - | 802.80M | 292.90M | 292.90M | 118.90M | 98.30M | 169.80M |
| Inventory | - | - | - | - | 524.10M | - | 577.80M | 533.70M | 577.60M |
| Receivables | - | - | - | - | 453.90M | - | 303.30M | 282.40M | 417.00M |
| Total Liabilities | - | - | - | 501.00M | 3.92B | 3.92B | 3.56B | 3.44B | 3.85B |
| Current Liabilities | - | - | - | 323.50M | 1.01B | 1.01B | 833.80M | 998.80M | 966.10M |
| Long Term Debt | - | - | - | - | 2.43B | 2.65B | 2.27B | 2.14B | 2.47B |
| Total Debt | - | - | - | - | 2.85B | - | 2.61B | 2.68B | 2.83B |
| Total Equity | 559.90M | 1.33B | - | 1.93B | 4.93B | 4.93B | 5.01B | 2.98B | 1.92B |
| Shares Outstanding | - | - | - | - | 66.40M | - | 66.70M | 67.26M | 67.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 629.70M | - | 805.90M | 885.30M | 885.30M | 280.20M | 83.00M | 105.20M |
| Investing Cash Flow | -63.30M | - | -319.50M | -1.64B | -1.64B | -187.60M | -149.90M | -192.70M |
| Financing Cash Flow | -130.30M | - | -173.10M | 252.00M | 252.00M | -265.80M | 48.80M | 155.80M |
| Capital Expenditure | -64.90M | - | -292.80M | -140.90M | -140.90M | -209.30M | -195.10M | -188.20M |
| Free Cash Flow | 564.80M | - | 513.10M | 744.40M | 744.40M | 70.90M | -112.10M | -83.00M |
| Net Change in Cash | - | - | - | -506.90M | - | -173.20M | -18.10M | 68.30M |
| Share Buybacks | 43.70M | - | 103.50M | - | 74.30M | 7.20M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 59.3% | - | 49.9% | 46.2% | 46.7% |
| Operating Margin % | 63.8% | - | 53.3% | 30.1% | 25.8% | 8.6% | 1.6% | 2.0% |
| Net Margin % | 48.8% | - | 41.5% | 16.8% | 16.8% | -0.3% | -73.7% | -41.5% |
| ROE % | 60.8% | - | 36.5% | 11.1% | 11.1% | -0.2% | -68.8% | -58.9% |
| ROCE % | - | - | 43.0% | 12.5% | 10.7% | 3.3% | 0.8% | 1.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.32% | 10.45M | $136.05M |
| 2 | FMR, LLC | 9.67% | 6.59M | $85.82M |
| 3 | T. Rowe Price Investment Management, Inc. | 8.26% | 5.63M | $73.30M |
| 4 | Newtyn Management, Llc | 6.68% | 4.56M | $59.35M |
| 5 | Vanguard Portfolio Management LLC | 5.91% | 4.03M | $52.49M |
| 6 | Rubric Capital Management LP | 4.85% | 3.31M | $43.05M |
| 7 | Invesco Ltd. | 4.57% | 3.12M | $40.59M |
| 8 | Vanguard Capital Management LLC | 4.48% | 3.05M | $39.75M |
| 9 | Dimensional Fund Advisors LP | 4.47% | 3.05M | $39.69M |
| 10 | American Century Companies Inc | 4.19% | 2.86M | $37.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QDEL